Published June 25, 2020 | Version v1
Journal article Open

Etanercept induced Bullous pemphigoid skin lesion in rheumatoid arthritis: A case report

  • 1. Rheumatologist. Rheumatology unit in Basra Teaching Hospital Basra. Iraq
  • 2. Dermatologist. Dermatology unit in Basra Teaching Hospital Basra. Iraq
  • 3. Rheumatologist, Rheumatology unit in Al sader Teaching Hospital, Basra. Iraq

Description

Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine produced predominantly by activated macrophages, and involved in the up-regulation of inflammatory reactions, and plays a pivotal role in the pathogenesis of rheumatoid arthritis and some other autoimmune disorders. Since their introduction anti-TNF-α agents have been revolutionized the treatment of these disorders. However, some adverse events such as skin reaction, hypersensitivity, infection, reactivation of tuberculosis, and various autoimmune diseases can occur in patients using these agents. In this report, we present a female case who was diagnosed as bullous pemphigoid while receiving etanercept for treatment of rheumatoid arthritis.

Files

Mathkhor et al.pdf

Files (158.6 kB)

Name Size Download all
md5:c9b263fd6ded2845be824f5cab43d7f6
158.6 kB Preview Download